Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.

Technology in cancer research & treatment - 1 Jan 2000

Du Zhen-Hua, Xia Yu, Yang Qing, Gao Song

Abstract excerpt

BACKGROUND AND OBJECTIVE: We have previously reported that BRCA2 N372 H i.a.1342A>C heterozygous variation presented in platinum-resistant patients. This study aimed to further investigate the mechanism of BRCA2 N372 H mutation in the development of platinum resistance in ovarian cancer. METHODS: The BRCA2 N372 H i.a.1342A>C was synthesized and used to exchange 1 wildtype allele followed by sequencing to confirm...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to BRCA2 Protein
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cisplatin

Share to Dose-Response Relationship, Drug

Share to Drug Resistance, Neoplasm

Share to Ovarian Neoplasms

Share to Rad51 Recombinase

Source

Open in PubMed Open full text

Identifiers

PMID: 33357097
DOI: 10.1177/1533033820983289
PMCID: PMC7768310

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The BRCA2 p.N372 H i.a.1342A>C Could Regulate the Sensitivity of Ovarian Cancer Cells to Platinum-Based Drugs.PMID 33357097Read ↗

[Application value of DNA damage repair variants in adjuvant therapy of triple negative breast cancer].Semantic proximity Read ↗

BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction.Semantic proximity Read ↗

BRCA2 N372H Polymorphism and Risk of Epithelial Ovarian Cancer: An Updated Meta-Analysis With 2344 Cases and 9672 Controls.Semantic proximity Read ↗

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.Semantic proximity Read ↗

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcomeSemantic proximity Read ↗

Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapySemantic proximity Read ↗

A highly annotated database of genes associated with platinum resistance in cancerSemantic proximity Read ↗

Construction and Validation of a Platinum Sensitivity Predictive Model With Multiple Genomic Variations for Epithelial Ovarian CancerSemantic proximity Read ↗

BRCA gene amplification in primary peritoneal high-grade serous carcinoma patient with intrinsic resistance to platinum treatment: a case report.Semantic proximity Read ↗

Platinum Resistance in Ovarian Cancer: Role of DNA RepairSemantic proximity Read ↗

TOP2A is a potential biomarker and promotes platinum drug resistance in ovarian cancer: a bioinformatics and experimental analysisSemantic proximity Read ↗

Association between polymorphisms in CTR1, CTR2, ATP7A, and ATP7B and platinum resistance in epithelial ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.